Oxford BioMedica plc (GB:OXB)
LSE:OXB
Want to see GB:OXB full AI Analyst Report?
Top Page
Oxford BioMedica
(LSE:OXB)
Select Model
Select Model
Rating:43Neutral
Price Target:
603.00 p
â–²(4.87% Upside)
Action:Reiterated
Date:03/27/26
The score is held back primarily by weak financial performance (still loss-making with negative operating/free cash flow despite improvement) and bearish technicals (price below key moving averages with negative MACD and weak RSI). Valuation provides limited support due to negative earnings and no dividend yield data.
Positive Factors
Specialized viral-vector CDMO capabilities
Oxford BioMedica's core business is specialized CDMO services for lentiviral and AAV vectors with dedicated manufacturing facilities and technical platforms. That niche expertise creates high technical barriers to entry and supports durable, contract-based revenue from gene and cell therapy developers.
Negative Factors
Persistent unprofitability
Despite revenue improvement, the company remains loss-making with negative operating and net margins. Continued unprofitability limits retained-earnings accumulation and requires either sustained margin expansion or external funding before the business can self-finance growth or pay down leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized viral-vector CDMO capabilities
Oxford BioMedica's core business is specialized CDMO services for lentiviral and AAV vectors with dedicated manufacturing facilities and technical platforms. That niche expertise creates high technical barriers to entry and supports durable, contract-based revenue from gene and cell therapy developers.
Read all positive factors
Oxford BioMedica (OXB) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£734.34M
Dividend YieldN/A
Average Volume (3M)323.90K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue Growth31.01%
EPS Growth31.72%
CountryUK
Employees850
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.29
Shares Outstanding121,010,340
10 Day Avg. Volume339,869
30 Day Avg. Volume323,903
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)7.56
Price to Sales (P/S)4.09
P/FCF Ratio-67.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£998.50Price Target Upside73.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.12
Revenue Forecast (FY)£227.87M
Oxford BioMedica Business Overview & Revenue Model
Company Description
Oxford Biomedica plc is a biopharmaceutical firm focused on the discovery, advancement, and sophisticated bioprocessing of innovative cell and gene therapies. Operating globally, with a strong presence across Europe, the company organizes its acti...
How the Company Makes Money
Oxford BioMedica makes money primarily by providing contract development and manufacturing services (CDMO) for viral vectors used by biopharmaceutical partners. Key revenue streams typically include: (1) Process and analytical development services...
Oxford BioMedica Earnings Call Summary
Earnings Call Date:Apr 09, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Sep 23, 2026
Earnings Call Sentiment Positive
The earnings call presented a positive outlook with significant revenue growth, increased client orders, operational efficiency improvements, and strategic expansions. However, challenges such as the operating EBITDA loss and negative working capital movement were noted.Positive Updates
Impressive Organic Revenue Growth
The company achieved an organic revenue growth of 81% and total revenues increased by 44% to GBP128.8 million in 2024.
Negative Updates
Operating EBITDA Loss
Despite improvements, the company reported an operating EBITDA loss of GBP15.3 million for 2024.
Read all updates
Q4-2024 Updates
Positive
Negative
Impressive Organic Revenue Growth
The company achieved an organic revenue growth of 81% and total revenues increased by 44% to GBP128.8 million in 2024.
Read all positive updates
Company Guidance
In the 2024 analyst briefing, OXB reported strong financial performance with an impressive organic revenue growth of 81%, resulting in total revenues of GBP128.8 million, a 44% increase from the previous year. Their pipeline expanded by 30% to $570 million, and customer orders grew by 35% to GBP186 million. The company achieved an operating EBITDA profit of GBP5 million in the second half of the year, narrowing their annual operating EBITDA loss to GBP15.3 million, a significant improvement from 2023's GBP52.8 million loss. For 2025, OXB expects revenues between GBP160 million and GBP170 million, with over 80% of this already covered by existing orders. The company plans to achieve a low single-digit million operating EBITDA profit, with a focus on continued margin expansion driven by operational efficiencies and strong commercial momentum.Oxford BioMedica Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
46
Neutral
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 168.74M | 128.80M | 89.54M | 139.99M | 142.80M |
| Gross Profit | 65.98M | 53.02M | 39.73M | 69.18M | 82.64M |
| EBITDA | -9.12M | -14.33M | -148.62M | -10.80M | 33.22M |
| Net Income | -30.13M | -43.19M | -157.49M | -39.16M | 19.01M |
Balance Sheet | |||||
| Total Assets | 325.72M | 231.64M | 252.34M | 460.18M | 237.23M |
| Cash, Cash Equivalents and Short-Term Investments | 96.88M | 60.65M | 103.72M | 141.31M | 109.02M |
| Total Debt | 148.13M | 108.76M | 111.46M | 114.28M | 9.34M |
| Total Liabilities | 234.37M | 171.16M | 174.51M | 223.99M | 49.89M |
| Stockholders Equity | 91.35M | 57.05M | 74.01M | 204.65M | 187.34M |
Cash Flow | |||||
| Free Cash Flow | -10.21M | -58.12M | -38.35M | -28.91M | 15.99M |
| Operating Cash Flow | -5.45M | -50.63M | -28.52M | -12.62M | 25.45M |
| Investing Cash Flow | -8.10M | 5.63M | 2.81M | -56.46M | -9.46M |
| Financing Cash Flow | 50.59M | 2.91M | -12.70M | 98.62M | 46.21M |
Oxford BioMedica Technical Analysis
Negative
575.00
Price Trends
613.36
Negative
654.11
Negative
648.13
Negative
Market Momentum
-3.25
Positive
46.42
Neutral
32.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OXB, the sentiment is Negative. The current price of 575 is below the 20-day moving average (MA) of 609.20, below the 50-day MA of 613.36, and below the 200-day MA of 648.13, indicating a bearish trend. The MACD of -3.25 indicates Positive momentum. The RSI at 46.42 is Neutral, neither overbought nor oversold. The STOCH value of 32.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:OXB.
Oxford BioMedica Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | £316.44M | -0.38 | -31.83% | ― | -5.89% | -310.69% | |
53 Neutral | £215.34M | -39.06 | 90.29% | ― | ― | 69.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £344.28M | -8.36 | -2929.47% | ― | ― | ― | |
46 Neutral | £23.60M | 35.54 | -197.54% | ― | 3.31% | 21.91% | |
43 Neutral | £734.34M | -21.32 | -48.56% | ― | 31.01% | 31.72% | |
42 Neutral | £54.20M | -4.93 | -2807.75% | ― | ― | -28.29% |
* Healthcare Sector Average
GB:OXB
Oxford BioMedica
600.00
293.00
95.44%
GB:AVCT
Avacta Group plc
73.00
41.00
128.13%
GB:PRTC
PureTech Health
131.40
3.20
2.50%
GB:SCLP
Scancell Holdings
20.75
11.25
118.42%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
819.00
649.25
382.47%
GB:AREC
Arecor Therapeutics PLC
62.50
19.00
43.68%
Oxford BioMedica Corporate Events
Business Operations and Strategy
Oxford Biomedica outlines long-term growth ambitions at Capital Markets Event
Positive
Jun 2, 2026
Oxford Biomedica will host a Capital Markets Event in London and online to showcase how its global, multi-vector CDMO platform is positioned to capture rising demand in the cell and gene therapy sector. Senior executives will outline the company&#...
Regulatory Filings and Compliance
Oxford Biomedica Sets Total Voting Rights at 121 Million Shares
Neutral
Jun 1, 2026
Oxford Biomedica has confirmed that its issued share capital at the close of business on 31 May 2026 comprised 121,010,337 ordinary shares, with no shares held in treasury. This establishes the company’s total voting rights at 121,010,337, a...
Business Operations and StrategyExecutive/Board Changes
Oxford Biomedica Director Joins Board of Nasdaq-Listed Stevanato Group
Positive
May 27, 2026
Oxford Biomedica, the FTSE250-listed cell and gene therapy CDMO, has built its business around advanced viral vector technologies, including lentiviral and AAV platforms, supported by strong quality systems and regulatory expertise. Its multinatio...
Regulatory Filings and Compliance
Oxford Biomedica Executives Exercise Deferred Bonus Options and Sell Shares
Neutral
May 22, 2026
Oxford Biomedica disclosed that Chief Legal Officer and Group Company Secretary Natalie Walter has exercised 3,816 Deferred Bonus Plan share options at a nil exercise price and subsequently sold the same number of ordinary shares at an average pri...
Other
Oxford Biomedica reports PDMR share dealing by senior HR executive
Neutral
May 19, 2026
Oxford Biomedica, a FTSE250-listed cell and gene therapy CDMO, provides viral vector technologies such as its TetraVecta lentiviral system and dual-plasmid AAV platform, underpinned by extensive regulatory and quality capabilities. Its geographica...
Regulatory Filings and Compliance
Oxford Biomedica Executives Exercise Options and Sell Shares in Routine PDMR Dealings
Neutral
May 13, 2026
Oxford Biomedica, a leading cell and gene therapy CDMO listed in London, develops and manufactures viral vectors for pharmaceutical and biotechnology clients across major global hubs. The group leverages proprietary platforms and deep regulatory a...
Business Operations and StrategyShareholder Meetings
Oxford Biomedica shareholders back all AGM resolutions, reinforcing strategic flexibility
Positive
May 7, 2026
Oxford Biomedica said all resolutions proposed at its 7 May annual general meeting in Oxford were approved by poll, confirming shareholder support for the company’s governance and strategic direction. Investors backed the adoption of the 202...
Regulatory Filings and Compliance
Oxford Biomedica Confirms Total Voting Rights at 120.9 Million Shares
Neutral
May 1, 2026
Oxford Biomedica has confirmed that its issued share capital at the close of business on 30 April 2026 comprises 120,920,518 ordinary shares, all carrying voting rights and with none held in treasury. This figure establishes the company’s cu...
Business Operations and StrategyDelistings and Listing Changes
Oxford Biomedica Adds Employee Scheme Shares to London Listing
Neutral
Apr 30, 2026
Oxford Biomedica has admitted 40,801 new ordinary shares of 50p each to trading on the London Stock Exchange’s Main Market, following their allotment under the company’s long-term incentive, Sharesave and employee share option schemes....
Business Operations and StrategyDelistings and Listing Changes
Oxford Biomedica Seeks Admission of New Shares Linked to Staff Incentive Plans
Neutral
Apr 27, 2026
Oxford Biomedica has applied to the London Stock Exchange for the admission to trading of 40,801 new ordinary shares, which have been allotted under its long-term incentive, sharesave and employee share option schemes. The new shares, expected to ...
Business Operations and StrategyProduct-Related Announcements
Oxford Biomedica unveils fast-track viral vector service to speed gene therapy development
Positive
Apr 13, 2026
Oxford Biomedica has introduced a new fast-track development and manufacturing service for lentiviral and adeno-associated viral vectors, aimed at biotechs facing tight timelines and funding constraints. Using its inAAVate and LentiVector platform...
Business Operations and StrategyExecutive/Board Changes
Oxford Biomedica Reinstates and Grants New Performance‑Linked Share Awards to Leadership
Positive
Apr 8, 2026
Oxford Biomedica has granted nil‑cost share options under its 2024 Long Term Incentive Plan and 2024 Deferred Bonus Plan to senior executives and key managers, including CEO Frank Mathias and CFO Lucinda Crabtree. The awards, which cover LTI...
Regulatory Filings and Compliance
Oxford Biomedica Confirms Updated Total Voting Rights
Neutral
Apr 1, 2026
Oxford Biomedica has confirmed that its issued share capital at the close of business on 31 March 2026 comprised 120,900,850 ordinary shares, with none held in treasury. As a result, the company’s total number of voting rights is 120,900,850...
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
Oxford Biomedica sets date for 2026 AGM as it underscores cell and gene therapy CDMO role
Positive
Mar 30, 2026
Oxford Biomedica has notified shareholders that its 2026 Annual General Meeting will be held on 7 May 2026 at the company’s Oxford headquarters, with the AGM notice and the 2025 annual report and accounts now dispatched and made available on...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Oxford BioMedica Returns to Profit as U.S. Expansion and Big Pharma Deals Lift Outlook
Positive
Mar 26, 2026
Oxford BioMedica reported a strong 2025 performance, with constant-currency revenue up 33% to £170.9 million and a return to positive Operating EBITDA, underpinned by growth in manufacturing, development and procurement services. Profitabilit...
Business Operations and Strategy
Oxford Biomedica licenses viral vector platforms to Australian CDMO VVMF
Positive
Mar 18, 2026
Oxford Biomedica has signed a five-year licensing and option agreement with Viral Vector Manufacturing Facility, Australia’s first dedicated commercial viral vector CDMO, granting it a worldwide, non-exclusive licence to OXB’s inAAVate...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.